Retatrutide (5mg)

What is Retatrutide?

Retatrutide, also known as LY3437943, is a peptide studied for activity at GIP, GLP-1 and glucagon receptors. This catalog lists a 5mg research vial. Triple receptor activity describes its research mechanism, not a guaranteed outcome.

Listed vial contents: 5mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.

What mechanisms are being studied?

Glucagon receptor activity distinguishes retatrutide from a GIP/GLP-1 dual agonist. Researchers examine how three receptor signals interact in metabolic models. The balance of those signals depends on the assay and experimental conditions.

What are the research questions?

• GIP, GLP-1 and glucagon receptor activation
• Receptor balance in multi-target compounds
• Comparing cellular signaling with human trial endpoints

What does the published work describe?

Jastreboff and colleagues reported a randomized phase 2 obesity trial in 2023. The study evaluated body-weight outcomes and adverse events over 48 weeks. It did not directly compare retatrutide with tirzepatide, and it did not test this supplied vial.

Experimental models in the cited papers

• Randomized phase 2 human trial; adults with obesity

What could future research explore?

Future work can investigate the contribution of each receptor and the reproducibility of multi-target responses. Claims about comparative treatments need direct trials; differences between separate trial averages do not establish a winner.

These are research directions, not established applications of the product sold here.

What are the limits of this evidence?

Clinical findings apply to the tested formulation, trial population and study conditions. They do not establish the identity, safety or effectiveness of this laboratory vial. Research Use Only: this material is not a finished medicine.

Study references

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023. PMID 37366315

How should I check lot documentation?

Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.

How is Retatrutide handled in the lab?

Plan a Retatrutide stock solution from the sequence, the listed molecular weight (4603.27 g/mol) and, when reported for the same lot, net peptide content. Test-dissolve a small portion first, store the powder sealed, cold and dry, and split solutions into single-use aliquots. These are laboratory handling notes, not administration guidance.

• Peptide solubility: choosing a lab solvent
• Stock solution molarity and concentration math
• Lyophilized storage, aliquoting and freeze-thaw
• Fmoc vs Boc synthesis and the impurities they leave